Key facts
- This page summarizes Robert E. Landry's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Aug 2023, 16:02.
Robert E. Landry - 23 Aug 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)
- Reporting relationship
- EVP Finance CFO
- Issuer ticker
- REGN
- Reported as of
- 23 Aug 2023
- Net transaction value
- -$188,212
- SEC form
- 4
- Accepted by SEC
- 25 Aug 2023, 16:02:53 UTC
- Prior SEC filing
- 29 Mar 2023
- Next SEC filing
- 12 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/**Robert E. Landry
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Landry filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 25 Aug 2023.
Change
- Previous filing in this sequence was filed on 29 Mar 2023.
- Current net transaction value: -$188,212.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
REGN
transaction
Common Stock
Sale
- Transaction value
- $188,212
- Shares
- -223
- Change %
- -0.7%
- Price
- $844.00
- Shares after
- 31,699
- Date
- 23 Aug 2023
- Ownership
- Direct
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 270
- Date
- 23 Aug 2023
- Ownership
- By 401(k) Plan
* marks a reported price that did not pass the local price check.